Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med. 2008;358:1547 59. 28. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-re- ceptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Lancet. 2008;372:1174 83. 29. Entresto [package insert]. Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015. 30. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejec- tion fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387 95. 31. Packer M, Califf RM, Konstam MA, et al. Comparison of omapa- trilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reduc- ing Events (OVERTURE). Circulation. 2002;106:920 6. 32. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enala- pril in patients with hypertension: the Omapatrilat Cardiovas- cular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103 11. 33. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin- angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2:663 70. 34. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio- oedema. Lancet. 2000;356:608 9. 35. Braunwald E. The path to an angiotensin receptor antagonist-ne- prilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015;65:1029 41. 36. Ruilope LM, Dukat A, B hm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, ac- tive comparator study. Lancet. 2010;375:1255 66. 37. B hm M, Robertson M, Ford I, et al. 